Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib
datasetposted on 2020-02-24, 13:45 authored by Greta Bagnolini, Domenico Milano, Marcella Manerba, Fabrizio Schipani, Jose Antonio Ortega, Dario Gioia, Federico Falchi, Andrea Balboni, Fulvia Farabegoli, Francesca De Franco, Janet Robertson, Roberto Pellicciari, Isabella Pallavicini, Sebastiano Peri, Saverio Minucci, Stefania Girotto, Giuseppina Di Stefano, Marinella Roberti, Andrea Cavalli
Synthetic lethality is an innovative framework for discovering novel anticancer drug candidates. One example is the use of PARP inhibitors (PARPi) in oncology patients with BRCA mutations. Here, we exploit a new paradigm based on the possibility of triggering synthetic lethality using only small organic molecules (dubbed “fully small-molecule-induced synthetic lethality”). We exploited this paradigm to target pancreatic cancer, one of the major unmet needs in oncology. We discovered a dihydroquinolone pyrazoline-based molecule (35d) that disrupts the RAD51-BRCA2 protein–protein interaction, thus mimicking the effect of BRCA2 mutation. 35d inhibits the homologous recombination in a human pancreatic adenocarcinoma cell line. In addition, it synergizes with olaparib (a PARPi) to trigger synthetic lethality. This strategy aims to widen the use of PARPi in BRCA-competent and olaparib-resistant cancers, making fully small-molecule-induced synthetic lethality an innovative approach toward unmet oncological needs.
Read the peer-reviewed publication
Inhibits Homologous RecombinationNew RAD 51-BRCASynthetic Lethalitysmall-molecule-inducedPARPitarget pancreatic cancerPARP inhibitorsdihydroquinolone pyrazoline-based m...Molecule Disruptorlethalityolaparib-resistant cancersnovel anticancer drug candidatesBRCA 2 mutationBRCA mutationsparadigmpancreatic adenocarcinoma cell linePancreatic Canceroncology patients